{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:03:30Z","timestamp":1793930610098,"version":"4.8.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:00:00Z","timestamp":1553817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00665","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:36:10Z","timestamp":1553819770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":249,"title":["Immunopathogenesis of Behcet's Disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Bainan","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanfang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaut.2009.02.011","article-title":"Beh\u00e7et's disease\u2014a contemporary review","volume":"32","author":"Mendes","year":"2009","journal-title":"J Autoimmun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","article-title":"Behcet's disease: ocular effects and treatment","volume":"27","author":"Deuter","year":"2008","journal-title":"Prog Retinal Eye Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Behcet's disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/09273948.2011.634978","article-title":"HLA-B*51 and Beh\u00e7et disease","volume":"20","author":"Gul","year":"2012","journal-title":"Ocular Immunol Inflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case-control genetic association studies","volume":"61","author":"de Menthon","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","article-title":"Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7ets disease","volume":"42","author":"Remmers","year":"2010","journal-title":"Nat Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/13543784.2016.1181751","article-title":"New therapeutic solutions for Beh\u00e7et's syndrome","volume":"25","author":"Vitale","year":"2016","journal-title":"Expert Opin Invest Drugs."},{"key":"B8","first-page":"291","article-title":"Beh\u00e7et's disease: autoimmune or autoinflammatory?","volume":"8","author":"Hedayatfar","year":"2013","journal-title":"J Ophthalmic Vis Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Behcet's disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"653539","DOI":"10.1155\/2014\/653539","article-title":"Immunopathogenesis of ocular Behcet's disease","volume":"2014","author":"Park","year":"2014","journal-title":"J Immunol Res."},{"key":"B11","first-page":"S27","article-title":"The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet's disease","volume":"25","author":"Mumcu","year":"2007","journal-title":"Clin Exp Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/ard.2003.017467","article-title":"The pustular skin lesions in Beh\u00e7et's syndrome are not sterile","volume":"63","author":"Hatemi","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/00365540410020730","article-title":"Evidence of chronic Chlamydia pneumoniae infection in patients with Behcet's disease","volume":"36","author":"Ayaslioglu","year":"2004","journal-title":"Scand J Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1067\/mjd.2001.117728","article-title":"HSP 60 expression in mucocutaneous lesions of Beh\u00e7et's disease","volume":"45","author":"Ergun","year":"2001","journal-title":"J Am Acad Dermatol."},{"key":"B15","first-page":"S44","article-title":"The role of heat shock proteins in Behcet's disease","volume":"21","author":"Direskeneli","year":"2003","journal-title":"Clin Exp Rheumatol."},{"key":"B16","first-page":"S96","article-title":"Serum levels of free heat shock protein 70 and anti-HSP70 are elevated in Beh\u00e7et's disease","volume":"26","author":"Birtas-Atesoglu","year":"2007","journal-title":"Clin Exp Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2249.2005.02760.x","article-title":"Alpha tropomyosin as a self-antigen in patients with Beh\u00e7et's disease","volume":"140","author":"Mahesh","year":"2005","journal-title":"Clin Exp Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/08830180212068","article-title":"Experimental autoimmune uveitides: multiple antigens, diverse diseases","author":"Adamus","year":"2002","journal-title":"Int Rev Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1167\/iovs.09-4313","article-title":"Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Beh\u00e7et's patients with uveitis","volume":"51","author":"Takeuchi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B20","first-page":"1456","article-title":"S-antigen specific T helper type 1 response is present in Behcet's disease","volume":"14","author":"Zhao","year":"2008","journal-title":"Mol Vis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.cdd.4402170","article-title":"NK cells at the interface between innate and adaptive immunity","volume":"15","author":"Moretta","year":"2007","journal-title":"Cell Death Diff."},{"key":"B22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaut.2012.05.006","article-title":"Regulatory NK cells in autoimmune disease","volume":"39","author":"Tian","year":"2012","journal-title":"J Autoimmun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/ar1034","article-title":"Natural killer cells and autoimmunity","volume":"6","author":"French","year":"2003","journal-title":"Arthritis Res Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/cei.12939","article-title":"Circulating NK cells and their subsets in Behcet's disease","volume":"188","author":"Hasan","year":"2017","journal-title":"Clin Exp Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1586\/eci.09.27","article-title":"Natural killer cells: versatile roles in autoimmune and infectious diseases","volume":"5","author":"Erten","year":"2009","journal-title":"Expert Rev Clin Immunol."},{"key":"B27","first-page":"S24","article-title":"Natural killer cells dominate a Th-1 polarised response in Behcet's disease patients with uveitis","volume":"33","author":"Kucuksezer","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/08820139.2017.1288240","article-title":"Natural killer cell subsets and their functional activity in Behcet's disease","volume":"46","author":"Cosan","year":"2017","journal-title":"Immunol Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar3005","article-title":"Natural killer cells control a T-helper 1 response in patients with Beh\u00e7et's disease","volume":"12","author":"Yamaguchi","year":"2010","journal-title":"Arthritis Res Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","article-title":"\u03b3\u03b4 T cells: first line of defense and beyond","volume":"32","author":"Chien","year":"2014","journal-title":"Ann Rev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.it.2009.09.001","article-title":"Monocytes and \u03b3\u03b4 T cells: close encounters in microbial infection","volume":"30","author":"Eberl","year":"2009","journal-title":"Trends Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1167\/iovs.10-6758","article-title":"Activated \u03b3\u03b4 T cells promote the activation of uveitogenic T cells and exacerbate EAU development","volume":"52","author":"Nian","year":"2011","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from \u03b3\u03b4 T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity."},{"key":"B34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0165-5728(02)00208-4","article-title":"V\u03b39V\u03b42 T cells recovered from eyes of patients with Beh\u00e7et's disease recognize non-peptide prenyl pyrophosphate antigens","volume":"130","author":"Verjans","year":"2002","journal-title":"J Neuroimmunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15961","DOI":"10.1074\/jbc.M008684200","article-title":"Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing eown-modulation of T cell antigen receptor","volume":"276","author":"Lafont","year":"2001","journal-title":"J Biol Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.humimm.2015.10.001","article-title":"In vitro evaluation of gammadelta T cells regulatory function in Behcet's disease patients and healthy controls","volume":"77","author":"Clemente Ximenis","year":"2016","journal-title":"Hum Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/ar4147","article-title":"Expression of regulatory receptors on \u03b3\u03b4 T Cells and their cytokine production in Behcet's disease","volume":"15","author":"Parlakgul","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nri1785","article-title":"Neutrophils and immunity: challenges and opportunities","volume":"6","author":"Nathan","year":"2006","journal-title":"Nat Rev Immunol."},{"key":"B39","first-page":"S19","article-title":"Neutrophil activation in Behcet's disease","volume":"19","author":"Eksioglu-Demiralp","year":"2001","journal-title":"Clin Exp Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2133.2004.06003.x","article-title":"Increased advanced oxidation protein products in Beh\u00e7et's disease: a new activity marker?","volume":"151","author":"Yazici","year":"2004","journal-title":"Br J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.intimp.2013.07.017","article-title":"Possible mechanisms of neutrophil activation in Beh\u00e7et's disease","volume":"17","author":"Neves","year":"2013","journal-title":"Int Immunopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.4049\/jimmunol.175.11.7678","article-title":"T cell-regulated neutrophilic inflammation in autoinflammatory diseases","volume":"175","author":"Keller","year":"2005","journal-title":"J Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1365-2559.2000.00859.x","article-title":"Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Beh\u00e7et disease","volume":"36","author":"Kobayashi","year":"2001","journal-title":"Histopathology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation."},{"key":"B45","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1346-8138.2003.tb00442.x","article-title":"Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Beh\u00e7et's disease","volume":"30","author":"Aridogan","year":"2003","journal-title":"J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","article-title":"Intraocular cytokine environment in active Behcet uveitis","volume":"142","author":"Ahn","year":"2006","journal-title":"Am J Ophthalmol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/jir.2011.0042","article-title":"Cytokines in autoimmune uveitis","volume":"31","author":"Horai","year":"2011","journal-title":"J Interferon Cytokine Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2230.2004.01684.x","article-title":"Serum interleukin 18 and tumour necrosis factor-\u03b1 levels are increased in Behcet's disease","volume":"30","author":"Oztas","year":"2005","journal-title":"Clin Exp Dermatol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00296-005-0029-8","article-title":"Serum interleukin-18 levels in patients with Beh\u00e7et's disease. Is its expression associated with disease activity or clinical presentations?","volume":"26","author":"Musabak","year":"2006","journal-title":"Rheumatol Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1167\/iovs.07-1390","article-title":"Upregulated IL-23 and IL-17 in Beh\u00e7et patients with active uveitis","volume":"49","author":"Chi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"E74","DOI":"10.3390\/jcm6070074","article-title":"The role of Th17 cells in the pathogenesis of Behcet's disease","volume":"6","author":"Nanke","year":"2017","journal-title":"J Clin Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"CR227","DOI":"10.12659\/MSM.881720","article-title":"Expression of Th-17 and ROR\u03b3t mRNA in Beh\u00e7et's disease","volume":"17","author":"Hamzaoui","year":"2011","journal-title":"Med Sci Monitor."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/ard.2009.119420","article-title":"IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population","volume":"69","author":"Jiang","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s10067-018-4049-7","article-title":"Correlation between IL-17A\/F, IL-23, IL-35 and IL-12\/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients","volume":"10","author":"Sonmez","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Ann Rev Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J Exp Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1074-7613(02)00295-9","article-title":"IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity","volume":"16","author":"Kasaian","year":"2002","journal-title":"Immunity."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.4049\/jimmunol.173.9.5361","article-title":"Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6","volume":"173","author":"Ozaki","year":"2004","journal-title":"J Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1182\/blood-2003-03-0669","article-title":"Interleukin-21 inhibits dendritic cell activation and maturation","volume":"102","author":"Brandt","year":"2003","journal-title":"Blood."},{"key":"B64","doi-asserted-by":"publisher","first-page":"9542","DOI":"10.1073\/pnas.1018182108","article-title":"Key role for IL-21 in experimental autoimmune uveitis","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B65","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/cmi.2010.22","article-title":"The cytokine milieu in the interplay of pathogenic Th1\/Th17 cells and regulatory T cells in autoimmune disease","volume":"7","author":"Leung","year":"2010","journal-title":"Cell Mol Immunol."},{"key":"B66","first-page":"S16","article-title":"Imbalance of Th17 to Th1 cells in Behcet's disease","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating Th17 and regulatory T cells in Behcet disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaci.2011.07.008","article-title":"Regulation of TH17 and regulatory T cells in patients with Behcet disease","volume":"128","author":"Direskeneli","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ni.1767","article-title":"Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells","volume":"10","author":"Duhen","year":"2009","journal-title":"Nat Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.autrev.2013.11.008","article-title":"Interleukin-22: a likely target for treatment of autoimmune diseases","volume":"13","author":"Yang","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11010-011-0772-y","article-title":"Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention","volume":"353","author":"Zhang","year":"2011","journal-title":"Mol Cell Biochem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e59009","DOI":"10.1371\/journal.pone.0059009","article-title":"Increased expression of IL-22 is associated with disease activity in Behcet's disease","volume":"8","author":"Cai","year":"2013","journal-title":"PLoS ONE."},{"key":"B75","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3109\/14397595.2013.879414","article-title":"IL-22-secreting Th22 and IFN-gamma-secreting Th17 cells in Behcet's disease","volume":"24","author":"Aktas Cetin","year":"2014","journal-title":"Modern Rheumatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/imr.12173","article-title":"Once a treg, always a treg?","volume":"259","author":"Sawant","year":"2014","journal-title":"Immunol Rev."},{"key":"B77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nri2916","article-title":"Phenotypic and functional specialization of FOXP3+ regulatory T cells","volume":"11","author":"Campbell","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/cmi.2015.12","article-title":"Regulatory T cells turn pathogenic","volume":"12","author":"Guo","year":"2015","journal-title":"Cell Mol Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jneuroim.2011.01.012","article-title":"RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behcet's disease","volume":"233","author":"Hamzaoui","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","article-title":"FOXP3+ regulatory T cells and their functional regulation","volume":"12","author":"Li","year":"2015","journal-title":"Cell Mol Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","article-title":"The regulation of IL-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Beh\u00e7et's disease: a comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimmun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.autrev.2017.08.001","article-title":"The Yin and Yang of regulatory T cell and therapy progress in autoimmune disease","volume":"16","author":"Qiao","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/09273948.2012.723109","article-title":"Roles of IL-10 in ocular inflammations: a review","volume":"20","author":"Ghasemi","year":"2012","journal-title":"Ocular Immunol Inflamm."},{"key":"B85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.autrev.2014.12.009","article-title":"IFN-\u03b1 induces IL-10 production and tilt the balance between Th1 and Th17 in Beh\u00e7et disease","volume":"14","author":"Touzot","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/keq330","article-title":"IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease","volume":"50","author":"Liu","year":"2011","journal-title":"Rheumatology."},{"key":"B88","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12016-015-8468-9","article-title":"IL-35 and autoimmunity: a comprehensive perspective","volume":"49","author":"Choi","year":"2015","journal-title":"Clin Rev Allergy Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cytogfr.2015.07.013","article-title":"Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases","volume":"26","author":"Egwuagu","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B90","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2018.01.017","article-title":"Emerging role of IL-35 in inflammatory autoimmune diseases","volume":"7","author":"Su","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/1043-4666(92)90028-P","article-title":"The role of cytokines in the pathogenesis of inflammatory eye disease","volume":"4","author":"Wakefield","year":"1992","journal-title":"Cytokine."},{"key":"B92","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/rheumatology\/keg232R","article-title":"Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease","volume":"42","author":"Karasneh","year":"2003","journal-title":"Rheumatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.imbio.2014.03.004","article-title":"Polymorphisms of interleukin 6 and interleukin 10 in Egyptian people with Behcet's disease","volume":"219","author":"Talaat","year":"2014","journal-title":"Immunobiology."},{"key":"B94","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.arcmed.2010.02.002","article-title":"TNF polymorphisms in patients with Behcet disease: a meta-analysis","volume":"41","author":"Touma","year":"2010","journal-title":"Arch Med Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bcp.2015.06.009","article-title":"Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers","volume":"97","author":"Ho","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature06878","article-title":"TGF-\u03b2-induced Foxp3 inhibits TH17 cell differentiation by antagonizing ROR\u03b3t function","volume":"453","author":"Zhou","year":"2008","journal-title":"Nature."},{"key":"B97","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-\u03b2 are required for differentiation of human TH17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature."},{"key":"B98","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine."},{"key":"B99","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.clineuro.2009.02.001","article-title":"CSF levels of cytokines in neuro-Beh\u00e7et's disease","volume":"111","author":"Borhani Haghighi","year":"2009","journal-title":"Clin Neurol Neurosurg."},{"key":"B100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"JR","year":"2008","journal-title":"J Pathol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"B102","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Beh\u00e7et's disease\u2014review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2017","journal-title":"Immunol Rev."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.autrev.2015.08.006","article-title":"Insights into IL-37, the role in autoimmune diseases","volume":"14","author":"Xu","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B107","first-page":"5371","article-title":"Regulatory effect of interleukin 37 in Behcet's disease","volume":"54","author":"Ye","year":"2013","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.imlet.2015.08.001","article-title":"Interleukin-37 expression is decreased in Beh\u00e7et's disease and is associated with inflammation","volume":"167","author":"Bouali","year":"2015","journal-title":"Immunol Lett."},{"key":"B109","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons,transforming growth factor b, and TNF-a: receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1189\/jlb.0609445","article-title":"Interleukin 27: a double-edged sword for offense and defense","volume":"86","author":"Yoshida","year":"2009","journal-title":"J Leukocyte Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/ni1540","article-title":"Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells","volume":"8","author":"Fitzgerald","year":"2007","journal-title":"Nat Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2567.2010.03379.x","article-title":"Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10","volume":"132","author":"Lee Yun","year":"2011","journal-title":"Immunology."},{"key":"B114","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar4570","article-title":"Decreased interleukin 27 expression is associated with active uveitis in Behcet's disease","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/jop.2011.0238","article-title":"Results of interferon alpha-2a therapy in patients with Behcet's disease","volume":"28","author":"Yalcindag","year":"2012","journal-title":"J Ocular Pharmacol Therapeut."},{"key":"B116","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00417-014-2856-3","article-title":"Anti-interferon alpha antibodies and autoantibodies in patients with Behcet's disease uveitis treated with recombinant human interferon alpha-2a","volume":"253","author":"Aydinoglu-Candan","year":"2015","journal-title":"Graefe Arch Clin Exp Ophthalmol."},{"key":"B117","first-page":"3","article-title":"One year in review 2017: Behcet's syndrome","volume":"35","author":"Hatemi","year":"2017","journal-title":"Clin Exp Rheumatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1097\/MIB.0b013e31828f19c9","article-title":"Efficacy of infliximab in intestinal Beh\u00e7et's disease","volume":"19","author":"Lee","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12969-017-0162-4","article-title":"Intestinal Behcet and Crohn's disease: two sides of the same coin","volume":"15","author":"Valenti","year":"2017","journal-title":"Pediatr Rheumatol."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Behcet's syndrome","author":"Esatoglu","year":"2019","journal-title":"Intern Emerg Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et's disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome\u2014a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/bor.0000000000000497","article-title":"Management of Behcet's disease","volume":"30","author":"Alibaz-Oner","year":"2018","journal-title":"Curr Opin Rheumatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T00:36:16Z","timestamp":1553819776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,29]]},"references-count":124,"alternative-id":["10.3389\/fimmu.2019.00665"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00665","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,29]]},"article-number":"665"}}